4//SEC Filing
Pivotal bioVenture Partners Fund I, L.P. 4
Accession 0001012975-20-000664
CIK 0001693011other
Filed
Jul 27, 8:00 PM ET
Accepted
Jul 28, 6:15 PM ET
Size
13.3 KB
Accession
0001012975-20-000664
Insider Transaction Report
Form 4
Transactions
- Conversion
Common Stock
2020-07-28+1,403,654→ 1,403,654 total(indirect: See footnote) - Purchase
Common Stock
2020-07-28$16.00/sh+187,500$3,000,000→ 1,591,154 total(indirect: See footnote) - Conversion
Series A-2 Convertible Preferred Stock
2020-07-28−10,489,510→ 0 total(indirect: See footnote)→ Common Stock (1,403,654 underlying)
Transactions
- Conversion
Series A-2 Convertible Preferred Stock
2020-07-28−10,489,510→ 0 total(indirect: See footnote)→ Common Stock (1,403,654 underlying) - Conversion
Common Stock
2020-07-28+1,403,654→ 1,403,654 total(indirect: See footnote) - Purchase
Common Stock
2020-07-28$16.00/sh+187,500$3,000,000→ 1,591,154 total(indirect: See footnote)
Transactions
- Conversion
Common Stock
2020-07-28+1,403,654→ 1,403,654 total(indirect: See footnote) - Conversion
Series A-2 Convertible Preferred Stock
2020-07-28−10,489,510→ 0 total(indirect: See footnote)→ Common Stock (1,403,654 underlying) - Purchase
Common Stock
2020-07-28$16.00/sh+187,500$3,000,000→ 1,591,154 total(indirect: See footnote)
Footnotes (2)
- [F1]On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). Robert Hopfner, Vincent Cheung, Peter Bisgaard, and Heather Preston are the managing partners of Pivotal's investment advisor and may be deemed to have shared voting and dispositive power over the securities owned by Pivotal. Such person's disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.
Documents
Issuer
Inozyme Pharma, Inc.
CIK 0001693011
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001695076
Filing Metadata
- Form type
- 4
- Filed
- Jul 27, 8:00 PM ET
- Accepted
- Jul 28, 6:15 PM ET
- Size
- 13.3 KB